BVS Bioventus

Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer

Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer

DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Dave Crawford as its Vice President, Investor Relations and Treasurer. Crawford has more than 20 years of experience across multiple areas of finance and comes to Bioventus from Avanos Medical, Inc. where he served for nearly seven years as its Vice President Treasurer, Investor Relations and Financial Planning and Analysis.

“We are happy to welcome Dave to lead our investor relations department and manage treasury at Bioventus,” said Greg Anglum, Senior Vice President and CFO. “Dave’s record of accomplishments, strong relationships within the financial community and career in finance and treasury are a perfect fit for the Company.”

Previously, Crawford spent several years in finance and treasury roles with Kimberly-Clark Corporation and was later promoted to Chief Financial Officer of the company’s Global Healthcare Division. Prior to that, Crawford held financial and treasury roles with Eli Lilly & Company. He began his career as a tax consultant with Arthur Andersen.

Crawford has an MBA from Duke University and received a Bachelor of Business Administration in Accounting from the University of Notre Dame.



About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment & joint preservation, restorative therapies and bone graft substitutes. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit , and follow the Company on and .



Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Media Contact:

Thomas Hill

Bioventus

919-474-6715

Investor Inquiries:

Mike Piccinino, CFA, IRC

Westwicke/ICR



EN
23/08/2021

Underlying

BVSBioventus

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioventus

 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthca...

Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2025, at 1:05 p.m. ET. A live webcast of the presentation will be available on the “Investors” section of the Company’s website at and will be available for replay on that site fol...

September 3, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growt...

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Tuesday, August 12, 2025, at 2:00 p.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the “Investors” section of the Company’s website at and will be available for...

August 7, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus Reports Second Quarter Financial Results

Bioventus Reports Second Quarter Financial Results Q2 reported revenue of $147.7 million declined 2.4%; Organic* revenue advanced 6.2%Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year periodNon-GAAP earnings* of $0.21 per share increased 31%Cash from operations of $25.9 million increased 71%Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for...

August 6, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus Enters into a New $400 Million Senior Secured Credit Agreeme...

Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- a global leader in innovations for active healing, today announced that it has entered into a $400 million Senior Secured Credit Agreement (the “Credit Agreement”) consisting of a $300 million term loan facility and a $100 million revolving credit facility on July 31, 2025. The new Credit Agreement will mature on July 31, 2030. Among the many enhancements, the new Credit Agreement provides for additional liqu...

August 4, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus Receives FDA 510(k) Clearances for two Next-Generation Perip...

Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both TalisMann™ and StimTrial™, expanding the Company’s innovative portfolio of Peripheral Nerve Stimulation (PNS) solutions for chronic pain management. These two clearances mark an important step forward for Bioventus and represent a substantial g...

July 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch